20-hydroxy-5,8,11,14-eicosatetraenoic acid has been researched along with aminoimidazole carboxamide in 1 studies
| Studies (20-hydroxy-5,8,11,14-eicosatetraenoic acid) | Trials (20-hydroxy-5,8,11,14-eicosatetraenoic acid) | Recent Studies (post-2010) (20-hydroxy-5,8,11,14-eicosatetraenoic acid) | Studies (aminoimidazole carboxamide) | Trials (aminoimidazole carboxamide) | Recent Studies (post-2010) (aminoimidazole carboxamide) |
|---|---|---|---|---|---|
| 640 | 13 | 233 | 1,913 | 35 | 830 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, K; Croft, KD; Keaney, JF; Li, C; Ward, NC | 1 |
1 other study(ies) available for 20-hydroxy-5,8,11,14-eicosatetraenoic acid and aminoimidazole carboxamide
| Article | Year |
|---|---|
Chronic activation of AMP-activated protein kinase prevents 20-hydroxyeicosatetraenoic acid-induced endothelial dysfunction.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Aorta; Cells, Cultured; Cytoprotection; Drug Evaluation, Preclinical; Endothelium, Vascular; Enzyme Activators; Humans; Hydroxyeicosatetraenoic Acids; Male; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase Type III; Phosphorylation; Proto-Oncogene Proteins c-akt; Ribonucleotides; Time Factors; Vascular Diseases; Vasoconstrictor Agents | 2011 |